Non-myeloablative stem cell transplants

British Journal of Haematology

Volumn 111, Issue 1, 2000, Pages 6-17

  Barrett, John ^a,b   Childs, Richard ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NHBI   (United States)

Author keywords

Allogeneic stem cell transplantation; Haematological malignancies; Non myeloablative; Renal cell cancer

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DISEASE COURSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; NOTE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD14; ANTIGENS, CD3; CARCINOMA, RENAL CELL; CLINICAL PROTOCOLS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; LUNG NEOPLASMS; MIDDLE AGED; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033759545     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02405.x     Document Type: Note

References (48)

1. Rapid reconstitution of T cell compartment after non myeloablative allogeneic stem cell transplantation (NMAT)
2. CD34 cell close predicts relapse and survival following T cell depleted HLA identical haematopoietic stem cell transplantation for haematological malignancies
3. Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies
4. Bone marrow transplantation for thalassemia - A preliminary report from the International Bone marrow transplant Registry
5. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia
6. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone
7. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy
8. Full donor chimerism predicts for graft-versus-host disease, graft-versus-marrow and graft-versus-malignancy effects following a non-myeloablative preparative regimen
9. Molecular remission of chronic myelogenous leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia (GVL) effect
10. Reduced toxicity and transplant-related mortality (TRM) following non-myeloablative peripheral blood stem cell transplantation for malignant disease
11. Regression of metastatic renal cell carcinoma after non-myeloablative allogenic peripheral blood stem cell transplantation
12. Durable mixed allogeneic chimerism and tolerance by a nonlethal irradiation-based cytoreductive approach
13. Solid cancers after bone marrow transplantation
14. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
15. Melphalan and purine analog containing preparative regimens: Less intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
16. Fludarabine phosphate and 2-chlorodeoxyadenosine: Immunosuppressive DNA synthesis inhibitors with potential application in islet allo-xenotransplantation
17. Cladribine (2-chlorodeoxyadenosine, CDA): An inhibitor of human B and T cell activation in vitro
18. Transplantation of anergic histocompatible bone marrow allografts
19. Aspects concerning busulfan pharmacokinetics and bioavailability
20. Factors affecting incidence and timing of cytomegalovirus (CMV) reactivation after allogeneic peripheral blood stem cell transplants (PBSCT)
21. Graft-versus-leukemia reactions after bone marrow transplantation
22. Nonmyeloablative T-cell depleted allogeneic peripheral blood stem cell (PBSC) transplantation for patients with chronic granulomatous disease
23. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new non-myeloablative drug combination
24. Transplant-lite: Induction of graft-versus-malignancy using a fludarabine-based nonablative chemotherapy and allogeneic blood progenitor transplantation as treatment for lymphoid malignancy
25. Transplant lite using fludarabinecyclophosphamide (FC) for low grade lymphoma, (LGL)
26. Low transplant-related acute complications in patients with CML undergoing allogeneic stem ceil transplantation with a low-dose (550cGy) total body irradiation (TBI) conditioning regimen
27. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
28. New horizons in the treatment of autoimmune diseases: Immunoablation and stem cell transplantation
29. +cell dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
30. Specific depletion of alloreactive T cells in HLA-identical siblings - A method for separating graft-versus-host and graft-versus-leukaemia reactions
31. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and post-graft cyclosporine and mycophenolate mofetil
32. Transfusion-associated graft-versus-host disease in fludarabine-treated lymphocytic leukaemia
33. Donor lymphocyte infusion post non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease
34. Metabolism and action of purine nucleoside analogs
35. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients
36. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen
37. Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymph node irradiation: Permanent survival of skin, heart, and marrow allografts
38. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
39. Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells
40. Bone marrow transplantation in malignant disease
41. Stable mixed chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and after pharmacologic immunosuppression after marrow transplantation
42. Stable mixed hematopoietic chimerism in dog leucocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
43. Stable mixed hematopoietic chimerism in dogs given donor antigen. CTLA-4 Ig and 100cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant
44. Hematopoietic cell transplantation for the induction of allo- and xenotolerance
45. Graft-versus-host related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoetic cells
46. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
47. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
48. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally-irradiated dogs given DLA nonidentical unrelated marrow grafts